Get started
Work

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Year: 2019
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2019-128977
Authors: Maureen M O'Brien, Lingyun Ji, Nirali N. Shah, Susan R. Rheingold, Deepa Bhojwani, Joanna S. Yi, Constance M. Yuan, Andrew C Harris, Patrick A. Brown, Michael J. Borowitz, Olga Militano, Meenakshi Devidas, Elizabeth A. Raetz, Lia Gore, Mignon L. Loh
Institutions: Cincinnati Children's Hospital Medical Center, University of Southern California, National Institutes of Health, National Cancer Institute, Children's Hospital of Philadelphia, University of Pennsylvania, Baylor College of Medicine, Texas Children's Hospital, Primary Children's Hospital, University of Utah, Johns Hopkins University, Children's Oncology Group, St. Jude Children's Research Hospital, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Children's Hospital Colorado, University of Colorado Anschutz, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W2990604751
Cites:
Cited by: 41
Related to: 10